Publication|Articles|November 18, 2026

Oncology® The Rad Onc Review

  • ONCOLOGY® The Rad Onc Review, Volume 1, Supplement 2
  • Volume 1
  • Issue 2
  • Pages: 4-5

Theranostics Moves Upfront: A New Chapter for Radiopharmaceutical Therapy

The FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI for adults with PSMA–positive metastatic APM–naive or -sensitive prostate cancer may represent a shift in the way clinicians think about treating cancer.

There are moments in oncology when an approval represents more than another treatment option. It signals a change in how we think about treating cancer. The July 31, 2026, FDA approval of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617; Pluvicto) in combination with an androgen receptor pathway inhibitor (ARPI) for adults with prostate-specific membrane antigen (PSMA)–positive metastatic androgen pathway modulation (APM)–naive or -sensitive prostate cancer may represent one of those moments.1 The subsequent incorporation of this approach into the NCCN Clinical Practice Guidelines in Oncology on August 27, 2026, further established radiopharmaceutical therapy as a consideration in the upfront metastatic setting.2

For the first time, PSMA-targeted radioligand therapy can be incorporated at the outset of treatment for metastatic prostate cancer rather than reserved for metastatic androgen receptor pathway modulator–resistant (APMR) disease. The potential implications are substantial: Radiopharmaceutical therapy is moving from a treatment encountered primarily later in a patient’s metastatic journey toward one that may now become part of its beginning.

The trajectory has been remarkable. In 2021, the phase 3 VISION trial (NCT03511664) demonstrated improved radiographic progression-free survival (rPFS) and overall survival with 177Lu-PSMA-617 in patients with PSMA-positive APMR prostate cancer previously treated with an ARPI and taxane chemotherapy, supporting the first FDA approval in March 2022.3 The phase 3 PSMAfore trial (NCT04689828) subsequently moved treatment earlier, demonstrating improved rPFS compared with a change in ARPI among taxane-naive patients with metastatic APMR prostate cancer and supporting expansion of the indication in March 2025.4 The phase 3 PSMAddition trial (NCT04720157) has now moved PSMA-targeted therapy earlier still.

In PSMAddition, 1144 patients with PSMA-positive metastatic APM-naive or -sensitive prostate cancer were randomly assigned to 177Lu-PSMA-617 plus androgen deprivation therapy (ADT) and an ARPI or ADT plus an ARPI alone. The study met its primary end point, with a 28% relative reduction in the risk of radiographic progression or death (HR, 0.72; 95% CI, 0.58-0.90).5 Benefit was observed across clinically important subgroups, including high- and low-volume and de novo and recurrent metastatic disease.

The population implications may be equally important. Moving radioligand therapy into metastatic APM-naive or -sensitive disease substantially expands the number of patients who could be considered for treatment. Although not every patient with metastatic disease will satisfy PSMA PET selection criteria or be an appropriate candidate, the eligible population may approach twice that of the previous indications. This creates opportunities for earlier precision treatment while simultaneously raising important questions about how best to integrate it into an increasingly complex metastatic prostate cancer landscape.

Many of those questions remain unanswered. Which patients derive the greatest incremental benefit from upfront radioligand therapy? How should we integrate 177Lu-PSMA-617 with chemotherapy, prostate-directed radiation therapy, metastasis-directed therapy, PARP inhibitors, and emerging systemic treatments? Should every patient receive 6 fixed-activity cycles, or might imaging, biomarkers, response-adapted strategies, and individualized dosimetry eventually tell us who needs fewer, or perhaps more, treatments?

Long-term toxicity also becomes increasingly important when treating patients earlier in their disease course, when anticipated survival may extend many years. PSMAddition demonstrated a generally manageable safety profile, but continued follow-up will be essential to better understand cumulative marrow, renal, and salivary toxicity as well as potential late effects.5 These questions should not temper enthusiasm for progress, but they should remind us that an approval is often the beginning of the next scientific conversation rather than its conclusion.

And that conversation extends far beyond 177Lu-PSMA-617. Radiopharmaceutical development is accelerating toward more targets, better targets, additional radioisotopes, individualized dosimetry, optimized administered activity, alternative treatment intervals, and more personalized numbers of treatment cycles. Alpha-emitting therapies are advancing rapidly, new theranostic targets continue to emerge, and principles established in prostate cancer and neuroendocrine tumors may ultimately provide a road map for extending radiopharmaceutical therapy across many malignancies.

Our infrastructure must evolve just as quickly. Expanding indications require sufficient radiopharmaceutical manufacturing capacity, treatment space, imaging infrastructure, radiation safety expertise, nuclear medicine technologists, physicists, nurses, advanced practice providers, and physicians trained to select, prescribe, manage, and longitudinally care for these patients. Theranostics cannot simply be added to existing oncology infrastructure without thoughtful investment in the people and systems required to deliver it safely and at scale.

For radiation oncology, this is an extraordinary opportunity. Our expertise in radiation biology, dosimetry, treatment planning, toxicity management, and multidisciplinary cancer care positions our specialty to contribute meaningfully to this next era. As I wrote in our inaugural issue, radiation oncology is a field in motion, increasingly integrating biological information and theranostics into precision cancer care.

Three FDA approvals for 177Lu-PSMA-617 across the metastatic prostate cancer continuum in little more than 4 years tell us something important: this field is moving quickly. Our challenge is not simply to keep pace, but to help determine where it goes next.

And that may be the most exciting part of all.

References

1. FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. FDA. July 31, 2026. Accessed September 21, 2026. https://tinyurl.com/4xzv5cyw

2. NCCN. Clinical Practice Guidelines in Oncology. Prostate cancer, version 7.2026. Accessed September 21, 2026. https://tinyurl.com/33423vk8

3. Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer.N Engl J Med.2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322

4. Morris MJ, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227-1239. doi:10.1016/S0140-6736(24)01653-2

5. Tagawa ST, Sartor O, Piulats JM, et al. [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial. Lancet. 2026;408(10557):793-807. doi:10.1016/S0140-6736(26)01092-5


Related to this article